Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study Evaluating the Efficacy of Elacestrant in Patients With Estrogen Receptor Positive Uterine Sarcomas

NCT07467772 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT07467772
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07467772 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study Evaluating the Efficacy of Elacestrant in Patients With Estrogen Receptor Positive Uterine Sarcomas
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 2
Overall status
Recruiting
Start date
March 25, 2026
Completion date
April 30, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial stromal sarcoma, ess, estrogen receptor positive tumor, perivascular epithelioid cell tumors, ulms, uterine adenosarcoma, uterine leiomyosarcoma, uterine pecoma, uterine sarcoma